Theodore Stewart Gourdin

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Andrea B. Apolo, John Ellerton, Jeffrey R. Infante et al. · Journal for ImmunoTherapy of Cancer · 2020 · 83 citations · Full text

Medicine, Oncology, Pharmacology +15

Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy

Hammad Shafqat, Theodore Stewart Gourdin, Amy Sion · Seminars in Oncology · 2018 · 68 citations

Life Sciences, Immunology, Oncology +16

Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy

Bhavana Bhatnagar, Vu H. Duong, Theodore Stewart Gourdin et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2013 · 56 citations

Medicine, Oncology, Pharmacology +13